FDA Granted Fast Track Status to PX578

The drug candidate targets POLG-mediated primary mitochondrial disorders.

Updated on Sept. 22, 2026 in Biotech

Isometric editorial illustration featuring a complex molecular structure model in muted teal and cream, representing advanced mitochondrial therapy research. — The FDA granted Fast Track Designation to PX578, a new therapy candidate from Pretzel Therapeutics intended to treat rare POLG-mediated mitochondrial disorders. AI Illustration. Upload story photo >

Live Poll

Should government regulators prioritize expedited drug reviews for rare diseases with no existing treatment options?

The FDA has granted Fast Track Designation to PX578, a small molecule therapy designed to treat POLG-mediated primary mitochondrial disorders. This regulatory move aims to expedite the development of a potential treatment for a condition that currently lacks approved disease-modifying options.

Why it matters

The designation acknowledges the significant unmet medical need for patients with these rare mitochondrial conditions. By facilitating more frequent interactions with federal regulators, the status could accelerate the pathway toward potential clinical approval.

PX578 acts as a CNS-penetrant small molecule activator of the mitochondrial polymerase POLG. It is designed to boost mitochondrial DNA levels to improve cellular energy production.

The players

FDA

This federal agency is responsible for protecting public health by ensuring the safety, efficacy, and security of human drugs and biological products.

Pretzel Therapeutics

This biotechnology company focuses on developing precision therapies to address mitochondrial dysfunction.

The details

Pretzel Therapeutics, based in Waltham, Massachusetts, developed PX578 as a targeted approach to address underlying cellular defects. The company previously completed a Phase 1 study in New Zealand and is preparing to launch the POLARIS study to evaluate the drug in adult patients.

September 22, 2026: The FDA granted Fast Track Designation to PX578.
Late 2026: Pretzel Therapeutics expects to initiate a Phase 2 clinical study.

Biotech
Sept. 23
FDA Granted Breakthrough Status to Glycomine Drug
Biotech
Sept. 22
Lexeo Therapeutics Acquired Mantle Therapeutics
Allergies
Sept. 18
FDA Approved Fayuvi for Sanfilippo Syndrome Type A

The Big Picture

The granting of this status follows the precedent established by the FDA Fast Track Designation program to streamline development for rare diseases. This regulatory mechanism is specifically intended to accelerate the delivery of novel therapies for conditions with significant unmet medical needs.

The designation may eventually provide a new treatment pathway for patients suffering from currently untreatable mitochondrial disorders. Patients and families affected by these conditions can anticipate more information as the drug enters Phase 2 clinical testing.

The takeaway

Fast Track status is a regulatory tool that helps shorten the time it takes to get new treatments from the lab to the clinic. It highlights how pharmaceutical companies are increasingly targeting rare genetic pathways to solve previously incurable diseases.